FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody or its antigen-binding fragment that specifically binds to the human gastric inhibitory polypeptide receptor (GIPR), as well as to a glucagon-like peptide-1 (GLP-1) fusion protein and a composition containing it. Also a polynucleotide encoding the said antibody and a polynucleotide encoding the said GLP-1 fusion protein, as well as a cell and a vector containing them are disclosed.
EFFECT: prevention or treatment of non-alcoholic fatty liver disease, prevention or treatment of type 2 diabetes mellitus, and also prevention or treatment of obesity.
27 cl, 5 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| IL-5 BINDING MOLECULE, METHOD OF ITS PREPARATION AND ITS USE | 2021 |
|
RU2811518C1 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| TETRAVALENT SYMMETRICAL BISPECIFIC ANTIBODIES | 2019 |
|
RU2807346C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
